Expert Commentary

Best age to begin screening mammograms: How I manage my patients

Author and Disclosure Information

I support individual preferences regarding screening for average-risk women in their 40s


 

References

Controversy has surrounded the utility of screening mammograms, particularly in women in their 40s. In 2009, the US Preventive Services Task Force recommended that screening mammography begin at age 50 and that women aged 50 to 74 receive a mammogram every 2 years.1 However, the American Cancer Society2 and other professional groups continue to recommend that annual screening begin at age 40, leading to controversy and confusion among women’s health clinicians and our patients.

In a recent study, Webb and colleagues3 used registry data based on a health plan in a single US city to assess the cause of death and mammogram history of 1,705 women who died following a diagnosis of invasive breast cancer from 1990 to 1999. They confirmed that 609 of these deaths were from breast cancer. How many of these patients were screened?

What did they find?
The investigators found that 29% of the 609 women who died from breast cancer had been screened for it—19% of the cancers that caused death were screen-detected and 10% were interval cancers. (Interval cancers were defined as symptomatic or palpable tumors that presented less than 2 years after the prior screening mammogram.) That means that 71% of 609 deaths from breast cancer were among unscreened women, with 6% of the fatal cancers diagnosed more than 2 years after the last mammogram and 65% never found upon screening because screening did not occur.

Among deaths caused (n = 609) and not caused (n = 905) by breast cancer, the median age at diagnosis was 49 and 72 years, respectively. Investigators concluded that regular screening of women younger than age 50 years would lower the death rate from breast cancer.

Related Article: Biennial vs annual mammography: How I manage my patients Andrew M. Kaunitz, MD (June 2013)

Let’s not jump to any conclusions
Although some may find the report by Webb and colleagues persuasive, I am concerned about this study’s limitations, of which there are a few. First, analyses that focus on women diagnosed with breast cancers do not allow comparison of outcomes among screened and unscreened populations.

Moreover, this report provides no information on ­treatment ­received by screened and unscreened women. It is likely that women who have never been screened, or who have been screened only infrequently, are considerably less affluent and less educated than women who are regularly screened. Accordingly, upon noting a palpable breast mass, unscreened women may be less likely to seek timely medical attention than regularly screened women, leading to differences in breast cancer outcomes, which are independent of screening history.

How I counsel my patients
For now, I will continue to be laissez-fare in my recommendations about screening mammograms for average-risk women in their 40s by supporting their individual preferences about when to initiate such screening.

Recommended Reading

BMN 673 monotherapy makes splash in BRCA-mutated ovarian, breast cancer
MDedge ObGyn
Endometrial Cancer Update: The move toward personalized cancer care
MDedge ObGyn
TRINOVA-1 signals new direction in ovarian cancer
MDedge ObGyn
ICON6 ovarian cancer results may resurrect cediranib
MDedge ObGyn
Many women with cancer not told about impaired fertility risk
MDedge ObGyn
USPSTF recommends tamoxifen or raloxifene to reduce breast cancer risk in high-risk patients
MDedge ObGyn
Hormone therapy’s protection against endometrial cancer persists in Women’s Health Initiative follow-up study
MDedge ObGyn
Which women are most likely to die from breast cancer—those screened annually starting at age 40, biennially starting at age 50, or not at all?
MDedge ObGyn
Single dose of HPV16/18 vaccine appears immunogenic
MDedge ObGyn
In phase III trial, bevacizumab prolongs progression-free survival for ovarian cancer
MDedge ObGyn

Related Articles